Tianjin Lisheng Pharmaceutical (SHE:002393) reported a net profit attributable to owners of 184.5 million yuan for the year 2024, down from 361.8 million yuan in the prior year.
Earnings per share fell to 0.72 yuan from 1.40 yuan a year ago, its parent company Tianjin Development Holdings (HKG:0882) said in a Friday filing with the Hong Kong bourse.
Total operating income, however, rose to 1.34 billion yuan from 1.15 billion yuan in the previous year.
The company proposed a 0.35 yuan per-share dividend, inclusive of taxes. The dividend is subject to approval by the shareholders.
Tianjin Lisheng's shares fell 3% in Shenzhen.
Price (HKD): $17.83, Change: $+0.15, Percent Change: +0.85%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.